Company intelligence / Profile preview

Pacylex Pharmaceuticals

Edmonton, Alberta, Canadapacylex.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Zelenirstat/PCLX‑001 has demonstrated good safety and significant progression-free/overall survival benefits in solid tumor patients during Phase I. In preclinical models, it outperformed standard-of-care treatments as a radiosensitizer in brain cancer. The drug triggers apoptosis/cell death even in resistant AML stem cells through multiple mechanisms. Clinical studies are ongoing with support from the US Department of Defense.

Therapeutic areas: Oncology
Modalities: Small molecules (N-myristoyltransferase inhibitors / NMTis)ADC payloads (for antibody-drug conjugates)
Industry: Biotech

Drug pipeline

1 asset

zelenirstat

Partnerships

University of Alberta (foundational research collaboration)University of Dundee (licensed family of high-quality myristoylation inhibitors)U.S. Department of Defense grant support for initial clinical investigation in AML patients

Beyond the preview

Go deeper on Pacylex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pacylex Pharmaceuticals.

Explore the full profile